Moreover, cancers driven by mutations in downstream pathway components do not respond to SMO inhibition, and thus there is a strong need for the identification of compounds that act downstream of SMO.[12, 13, 14] Epigenetic targeting of the Hedgehog pathway has emerged as an interesting strategy to combat (SMO‐inhibitor resistant) tumors. This evidence concerns the gene SMO and cancer.